Kathleen Shuey provides critical support and guidance in oncology nursing, leveraging over 25 years of experience. She ...

Fifteen years after being diagnosed with small lymphocytic lymphoma, I’ve found healing and meaning in the work I love and ...

Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on ...

After my breast cancer treatment, I started a clothing bank to give others free access to recovery items like post-surgery ...

I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact ...

Heather Patenaude, B.S.N., RN, displays the highest level of technical skills necessary to provide compassionate care to her ...

SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate ...

Proton therapy may reduce urinary, bowel and sexual side effects in prostate cancer by minimizing radiation exposure to ...

DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting ...

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and ...